Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24837668 | 0.92 | GAA (0.41) | HTTKDM4ETSHRGAALMNA | |
| SCHEMBL18159150 | 0.91 | HTT (0.42) | HTTKDM4ETSHRGAALMNA | |
| SCHEMBL20147315 | 0.82 | HTT (0.37) | HTTKDM4ETSHRGAALMNA | |
| SCHEMBL23369660 | 0.79 | HTT (0.44) | HTTKDM4ETSHRGAALMNA | |
| SCHEMBL12717161 | 0.77 | TSHR (0.36) | TSHRLMNASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL26754913 | 0.77 | — | — | |
| SCHEMBL26065167 | 0.77 | HTT (0.36) | HTTKDM4ETSHRGAALMNA | |
| SCHEMBL26754939 | 0.76 | KCNH2 (0.36) | — | |
| SCHEMBL26750780 | 0.76 | EPHX1 (0.33) | — | |
| SCHEMBL26750986 | 0.76 | KDM4E (0.32) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225302-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023220421-A1 | INHIBITORS OF KRAS(G12D) | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023020523-A1 | BICYCLIC DERIVATIVES AND USE THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022250170-A9 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-01-05 | — | — | WO | disclosed |
| US-9802921-B2 | Fluoromethyl-substituted pyrrole carboxamides iv | GRUENENTHAL GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| EP-2707361-B1 | FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9562036-B2 | Fluoromethyl-substituted pyrrole carboxamides as CaV2.2 calcium channel blockers | Grünenthal GmbH (DE) | 2017-02-07 | — | — | US | disclosed |
| US-20160297803-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES IV | GRUENENTHAL GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-20160289214-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS | Grünenthal GmbH (DE) | 2016-10-06 | — | — | US | disclosed |
| US-9302988-B2 | Fluoromethyl-substituted pyrrole carboxamides | Grünenthal GmbH (DE) | 2016-04-05 | — | — | US | disclosed |
| US-20140066426-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | GRUENENTHAL GMBH (DE) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289214-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNG2, CACNA1G | HTT 1182/4885KDM4E 1063/4885TSHR 4093/4885 |
| US-20140066426-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | TRPV1, CACNA1B, CACNA1G | HTT 906/4885KDM4E 808/4885TSHR 3479/4885 |
| US-20160297803-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES IV | TRPV1, CACNA1B, CACNA1I | HTT 1292/4885KDM4E 367/4885TSHR 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.